GSK plc (GSK.L) Monday said the European Commission has granted marketing authorization for Omjjara to treat myelofibrosis, a rare type of blood cancer.
Omjjara is the first medicine approved in the EU specifically for this indication.
The authorization of Omjjara was based on the MOMENTUM and SIMPLIFY-1 phase III trials
In September last year, Ojjaara was approved by the US Food and Drug Administration (FDA) for the treatment of myelofibrosis.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.